Results 41 to 50 of about 4,269 (177)

Development of a Novel 18F‐Labeled Radioligand for Imaging Translocator Protein With Positron Emission Tomography

iRADIOLOGY, EarlyView.
Translocator protein 18 kDa (TSPO) is a well‐established biomarker of neuroinflammation and is implicated in the pathophysiology of various neurodegenerative diseases. This study presents [18F]TSPO‐1118 ([18F]3) as a promising positron emission tomography (PET) radioligand for imaging TSPO with high affinity, robust brain uptake, and specificity in ...
Jian Rong, Chunyu Zhao, Xin Zhou, Jiahui Chen, Yabiao Gao, Zhendong Song, Yinlong Li, Zijing Li, Steven H. Liang   +8 more
wiley   +1 more source

A Modified Balanced Steady State Free Precession Sequence for Overhauser Magnetic Resonance Imaging

Magnetic Resonance in Medicine, EarlyView.
ABSTRACT Purpose Low‐ and ultralow‐field magnetic resonance imaging (ULF MRI) have inherently low signal‐to‐noise ratio (SNR) by design. Overhauser dynamic nuclear polarization (ODNP) stands out as an effective solution for continuous signal enhancement.
Kai Buckenmaier, Friedemann Bullinger, Georgiy Alekseevich Solomakha, Marcel Schneider, Jörn Engelmann, Philipp Pohlmann, Pavel Povolni, Laura Kuebler, André Ferreira Martins, Klaus Scheffler   +9 more
wiley   +1 more source

⁶⁸Ga Extemporaneous Preparations in Radiopharmacy. [PDF]

Pharmaceutics
Gallium-68 (68Ga) radiopharmaceuticals are increasingly used in nuclear medicine due to their rapid production capabilities and exceptional specificity in molecular imaging applications.
Rizzello M, Pacelli A, De Bari MD, Cutrignelli A, Iacobazzi RM, Lopalco A, Denora N.   +6 more
europepmc   +2 more sources

The Metamorphosis of Radionuclide Production and Development at Paul Scherrer Institute

CHIMIA, 2020
Radionuclide production and development has a long history at the Paul Scherrer Institute (PSI) and dates back to the founding times of its forerunner institutions: the Federal Institute for Reactor Research and the Swiss Institute for Nuclear Research ...
Pascal V. Grundler, Robert Eichler, Zeynep Talip, P. August Schubiger, Roger Schibli, Nicholas P. van der Meulen   +5 more
doaj   +1 more source

Radioiodination of Two Carborane‐Based Dual Cyclooxygenase‐2/5‐Lipoxygenase Inhibitors and Their In Vitro and In Vivo Evaluation

ChemBioChem, Volume 27, Issue 7, 14 April 2026.
Two dicarbadodecaborane(12)‐based dual cyclooxygenase‐2/5‐lipoxygenase (COX‐2/5‐LO) inhibitors were 123I‐labeled. Refinement of labeling and formulation conditions and extensive in vitro characterization are presented. Cell uptake studies in COX‐2‐ and 5‐LO‐overexpressing cell lines showed COX‐2‐independent and partly 5‐LO‐dependent uptake.
Jonas Schädlich, Martin Ullrich, Cathleen Haase‐Kohn, Robert Wodtke, Sebastian Braun, Maximilian Molitor, Bettina Hofmann, Dieter Steinhilber, Klaus Kopka, Evamarie Hey‐Hawkins, Jens Pietzsch, Markus Laube   +11 more
wiley   +1 more source

Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer

EJNMMI Radiopharmacy and Chemistry, 2023
Background The Affibody molecule, ABY-025, has demonstrated utility to detect human epidermal growth factor receptor 2 (HER2) in vivo, either radiolabelled with indium-111 (111In) or gallium-68 (68Ga).
Emma Jussing, Mélodie Ferrat, Mohammad M. Moein, Henrik Alfredéen, Tetyana Tegnebratt, Klas Bratteby, Erik Samén, Joachim Feldwisch, Renske Altena, Rimma Axelsson, Thuy A. Tran   +10 more
doaj   +1 more source

High‐resolution deuterium metabolic imaging of the human brain at 9.4 T using phase‐cycled balanced SSFP spectral–spatial acquisitions

Magnetic Resonance in Medicine, Volume 95, Issue 3, Page 1304-1322, March 2026.
Abstract Purpose The aim was to improve the sensitivity and robustness against B0 inhomogeneities of deuterium metabolic imaging (DMI) using phase‐cycled balanced SSFP (bSSFP) methods at 9.4 T. Methods We investigated two variants of phase‐cycled bSSFP acquisitions, namely uniformly weighted multi‐echo and acquisition‐weighted chemical shift imaging ...
Praveen Iyyappan Valsala, Rolf Pohmann, Rahel Heule, Georgiy A. Solomakha, Nikolai I. Avdievich, Jörn Engelmann, Laura Kuebler, André F. Martins, Klaus Scheffler   +8 more
wiley   +1 more source

Integrating Nuclear Medicine Services Into Health Care Systems in Low‐ and Middle‐Income Countries: A Review of Challenges and Innovations

iRADIOLOGY, Volume 4, Issue 1, Page 3-12, February 2026.
Nuclear medicine is capable of solving noncommunicable diseases in LMICs but poses its own challenges. Research and investments are still needed. For nuclear medicine to answer the dynamics of noncommunicable diseases in the LMICs, it would have to overcome the high costs and regulations involved in this practice.
Biruk Demisse Ayalew, Saim Mahmood Khan, Helina K. Teklehaimanot, Zebeaman Tibebu Gorfu, Biniyam Jemaneh Batu, Zemichael Getu Alemayehu, Brook Lelisa Sime, Eyerusalem Kebede Zewde, Temesgen Mamo Sharew, Muhidin Ibrahim Hundisa, Yeamlak Tariku Tewodros, Jawairya Muhammad Hussain, Barina Khan   +12 more
wiley   +1 more source

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

ChemBioChem, Volume 27, Issue 1, January 2026.
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh, Rupesh R. Kurhade, Abrar A. M. Siddiqui, Shaikh Shahbaz A. Majeed, Thomas J. Webster, Mohammad Intakhab Alam, Abdul Wasy Zia, Md. Faiyazuddin   +7 more
wiley   +1 more source

Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications

Medicinal Research Reviews, Volume 46, Issue 1, Page 203-237, January 2026.
ABSTRACT Targeted radioligand therapy has emerged as a promising treatment option for eradicating advanced cancer forms. α‐Emitters are considered particularly promising as they can obliterate (micro)‐metastases. The α‐emitter astatine‐211 (211At) has experienced increased interest due to its favorable decay properties.
Marius Müller, Nadia Bom Pedersen, Vladimir Shalgunov, Andreas Ingemann Jensen, Umberto Maria Battisti, Matthias Manfred Herth   +5 more
wiley   +1 more source